Robert Sims

With 20+ years of experience in the transcription field, including 10+ years in the drug discovery of gene control, Robert is passionate about working with diverse and talented teams to discover and develop novel transcription factor medicines.

As a founding scientist of Constellation Pharmaceuticals, he feels fortunate to have experienced and contributed to nearly all aspects of company creation— from concept to becoming a public company, with multiple programs in clinical development. While at Constellation, Robert led the discovery and translational efforts for Pelabresib, a BET bromodomain inhibitor now in phase 3 clinical development for the treatment of myelofibrosis.